Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Nam Hoon | - |
dc.contributor.author | Han, Ki Hoon | - |
dc.contributor.author | Choi, Jimi | - |
dc.contributor.author | Lee, Juneyoung | - |
dc.contributor.author | Kim, Sin Gon | - |
dc.date.accessioned | 2021-09-01T05:49:20Z | - |
dc.date.available | 2021-09-01T05:49:20Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2019-09-27 | - |
dc.identifier.issn | 1756-1833 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/62829 | - |
dc.description.abstract | OBJECTIVE To investigate whether fenofibrate as add-on to statin treatment reduce persistent cardiovascular risk in adults with metabolic syndrome in a real world setting. DESIGN Propensity matched cohort study. SETTING Population based cohort in Korea. PARTICIPANTS 29 771 adults with metabolic syndrome (>= 40 years) receiving statin treatment. 2156 participants receiving combined treatment (statin plus fenofibrate) were weighted based on propensity score in a 1:5 ratio with 8549 participants using statin only treatment. MAIN OUTCOME MEASURE Primary outcome was composite cardiovascular events including incident coronary heart disease, ischaemic stroke, and death from cardiovascular causes. RESULTS The incidence rate per 1000 person years of composite cardiovascular events was 17.7 (95% confidence interval 14.4 to 21.8) in the combined treatment group and 22.0 (20.1 to 24.1) in the statin group. The risk of composite cardiovascular events was significantly reduced in the combined treatment group compared with statin group (adjusted hazard ratio 0.74, 95% confidence interval 0.58 to 0.93; P=0.01). The significance was maintained in the on-treatment analysis (hazard ratio 0.63, 95% confidence interval 0.44 to 0.92; P=0.02). The risk of incident coronary heart disease, ischaemic stroke, and cardiovascular death was lower in the combined treatment group than statin group but was not significant. Participant characteristics did not appear to be associated with the low risk of composite cardiovascular events with combined treatment. CONCLUSION In this propensity weighted cohort study of adults with metabolic syndrome, the risk of major cardiovascular events was significantly lower with fenofibrate as add-on to statin treatment than with statin treatment alone. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | BMJ PUBLISHING GROUP | - |
dc.subject | RESIDUAL RISK | - |
dc.subject | DISEASE | - |
dc.subject | THERAPY | - |
dc.subject | EVENTS | - |
dc.subject | CHOLESTEROL | - |
dc.subject | METAANALYSIS | - |
dc.subject | REDUCTION | - |
dc.subject | MORTALITY | - |
dc.subject | SURVIVAL | - |
dc.subject | STRESS | - |
dc.title | Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Nam Hoon | - |
dc.contributor.affiliatedAuthor | Lee, Juneyoung | - |
dc.contributor.affiliatedAuthor | Kim, Sin Gon | - |
dc.identifier.doi | 10.1136/bmj.l5125 | - |
dc.identifier.scopusid | 2-s2.0-85072714417 | - |
dc.identifier.wosid | 000488490200001 | - |
dc.identifier.bibliographicCitation | BMJ-BRITISH MEDICAL JOURNAL, v.366 | - |
dc.relation.isPartOf | BMJ-BRITISH MEDICAL JOURNAL | - |
dc.citation.title | BMJ-BRITISH MEDICAL JOURNAL | - |
dc.citation.volume | 366 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | RESIDUAL RISK | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | EVENTS | - |
dc.subject.keywordPlus | CHOLESTEROL | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | REDUCTION | - |
dc.subject.keywordPlus | MORTALITY | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | STRESS | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.